Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin
Lonza Group AG / Key word(s): Half Year Results Ad hoc announcement pursuant to Art. 53 LR |
- In H1 2022, Lonza delivers CHF 3 billion sales and 16.8%1 CER sales growth
- CHF 987 million CORE EBITDA resulted in a margin of 33.1%
- H1 2022 CAPEX reached 28.2% of sales as Lonza continues to execute planned investments
- Group Outlook 2022 confirmed at low to mid-teens CER sales growth and CORE EBITDA margin improvement
- Mid-Term Guidance 2024 reconfirmed
Basel, Switzerland, 22 July 2022 – Lonza has reported sales of CHF 3 billion, growing 17.3% AER2 (16.8%1 CER) and CHF 987 million CORE EBITDA, resulting in a margin of 33.1%. Thanks to the commitment of colleagues across Lonza’s global network, the company has successfully navigated the challenges arising from the uncertain macroeconomic environment in the First Half. Lonza remains on track to deliver on its 2022 Outlook and reconfirms its Mid-Term Guidance 2024, assuming no unforeseen events or issues.
Lonza has announced an investment of approximately CHF 500 million to build a large-scale, commercial drug product fill and finish facility in Stein (CH). This fulfills the company’s strategic commitment to complete its value chain in Biologics, which allows customers to benefit from an end-to-end service. Throughout H1, the company continued its organic growth strategy, investing 28.2% of sales in CAPEX. This is in line with planned Full-Year CAPEX (around 30% of sales).
Lonza continues to advance its ESG agenda. 2022 is the first year in which Lonza has incorporated ESG targets into its employee and executive renumeration policies. Currently, the business is engaged in more than 100 ESG projects across the global network.
Lonza confirms its Outlook for Full-Year 2022 at low- to mid-teens CER sales growth and an overall CORE EBITDA margin improvement in line with the 2024 Mid-Term Guidance. This will be achieved by a combination of operational excellence and active management of inflation.